Comparative Pharmacology
Head-to-head clinical analysis: BETOPTIC PILO versus BRIMONIDINE TARTRATE TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BETOPTIC PILO versus BRIMONIDINE TARTRATE TIMOLOL MALEATE.
BETOPTIC PILO vs BRIMONIDINE TARTRATE; TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betoptic Pilo is a combination of betaxolol (a cardioselective beta-1 adrenergic receptor antagonist) and pilocarpine (a muscarinic cholinergic agonist). Betaxolol reduces aqueous humor production by blocking beta-adrenergic receptors in the ciliary epithelium. Pilocarpine increases aqueous humor outflow by contracting the ciliary muscle and opening the trabecular meshwork.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
One drop of 0.5% betaxolol and 4% pilocarpine combination ophthalmic solution instilled into the affected eye(s) twice daily.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
None Documented
None Documented
Betaxolol: 16–22 hours (clinical context: allows once-daily dosing for glaucoma). Pilocarpine: 0.5–1.5 hours (rapid elimination, requiring multiple daily dosing).
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Betoptic Pilo (betaxolol and pilocarpine) undergoes both renal and hepatic elimination. Betaxolol is primarily metabolized in the liver (active metabolites) with less than 15% excreted unchanged in urine. Pilocarpine is hydrolyzed in plasma and tissues; its metabolites and a small fraction of unchanged drug are excreted renally. Fecal excretion is negligible.
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Category C
Category A/B
Beta-Blocker
Beta-Blocker